Eisai-Biogen Alzheimer’s Therapy to Cost 2.98 million Yen Per Year
A single course of treatment with an Alzheimer’s drug developed by Japanese company Eisai Co. and U.S. firm Biogen Inc. will cost around 2.98 million yen ($20,500) per year in Japan and will be largely covered by public health insurance, a health ministry body said Wednesday.
As the drug, branded Leqembi, will be covered by public health insurance, those undergoing treatment will pay between 10 to 30 percent of the cost out of their own pocket, depending on their age and income.




